The Flag­ship train keeps chug­ging with its 'in­ter­sys­tem­s' play­er eye­ing the clin­ic next year with 3 new drugs

Flag­ship com­pa­nies like to move quick­ly these days. Just one day af­ter Va­lo Health an­nounced a move to Nas­daq via SPAC af­ter its un­veil­ing last Sep­tem­ber, an­oth­er Flag­ship biotech is putting the fin­ish­ing touch­es on a new fundraise.

Sen­da Bio­sciences closed their Se­ries B on Thurs­day morn­ing with $98 mil­lion in tow, the Cam­bridge, MA-based com­pa­ny said. The raise comes rough­ly sev­en and a half months since Flag­ship launched the biotech to ex­plore what they call “in­ter­sys­tems bi­ol­o­gy,” or the con­nec­tions be­tween how hu­mans co­e­volved with plants and bac­te­ria.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.